Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/23/2008
 
First Published:
6/22/2006
1.
Phase III Study of Risk-Based Therapy Comprising Observation Only, Adjuvant Radiotherapy, or Adjuvant Chemoradiotherapy or Neoadjuvant Chemoradiotherapy, Surgery, and Adjuvant Chemotherapy With or Without Radiotherapy in Young Patients With Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 30 at diagnosis
NCI
COG-ARST0332
ARST0332, NCT00346164
2.
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
30 and under
NCI, Other
OS2008
NCT00667342
3.
Deforolimus in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
13 and over
Pharmaceutical / Industry
AP23573-07-302
NCT00538239
4.
Trial of Dasatinib in Advanced Sarcomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 13
Other
SARC009
NCT00464620
5.
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
16 and over
Pharmaceutical / Industry
REO 014
NCT00503295
Last Modified:
9/17/2008
 
First Published:
11/5/2007
6.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
3 to 21
NCI
NCI-08-C-0007
08-C-0007, NCI-P6068, 7458, NCT00556881
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute